the relationships between EGFR expression and several pro- gnostic variables .. Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL. The relationship of quantitative epidermal growth factor receptor expression in non- small cell lung cancer to. There is a direct relationship between anti-EGF antibody titers and immune response Key words: cancer vaccine, epidermal growth factor, non-small-cell lung cancer .. Veale D, Kerr N, Gibson GJ et al. The relationship of quantitative. using less quantitative techniques for EGFR mRNA or protein expression failed to .. Veale, D., Kerr, N., Gibson, G., Kelly, P., and Harris, A. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung.
A second report found that although EGFR expression was the highest in squamous cell carcinomas, it could not be correlated with other clinicopathological characteristics such as histologic grade or stage In contrast, other investigators have reported significant correlations between EGFR expression and more aggressive tumor features, such as tumor stage 22 or nodal metastases In our study, no significant correlations were found between EGFR expression and several clinicopathological or biological parameters, including tumor size, nodal metastasis, histologic grade, and tumor angiogenesis.
There was a correlation, however, between EGFR expression and tumor cell proliferative activity, as measured with the Ki proliferation index. This index measures the proportion of cycling cells and is a potent biological marker for quantitative estimation of the growth of neoplasms EGFR has been reported to act as a strong prognostic marker in head and neck cancers 28genito-urinary carcinomas 2930 and esophageal cancers However, several studies using specimens from larger numbers of patients suggested that EGFR expression was not associated with poor outcome 1720 Because our study was retrospective and analyzed a relatively small number of tumors, we could not definitely determine the relationship between EGFR expression and long-term prognosis.
When combined with previous results, our findings suggest that EGFR may be more important for lung tumor formation than for tumor progression. Although EGFR expression may not be useful as a prognostic factor, it has potential clinical implications. The past few years have seen the rapid development of the EGFR inhibitors, and an increasing body of evidence suggests that selective inhibitors of EGFR are potential therapeutic agents for the treatment of NSCLC in adjuvant, metastatic and chemopreventive settings In conclusion, our data show no significant correlations between EGFR expression in NSCLC and other clinicopathological parameters such as tumor size, nodal metastasis, angiogenesis and prognosis.
BioMed Research International
Molecular and pathologic markers in stage I non-small cell carcinoma of the lung. J Clin Oncol ; Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Biological role of epidermal growth factor-receptor clustering: J Biol Chem ; Epidermal growth factor receptor status of histological sub-types of breast cancer.
Br J Cancer ; Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest ; Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer.
Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer.
There was a problem providing the content you requested
Epidermal growth factor receptor EGFr ; results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas. J Cancer Res Clin Oncol ; The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long-term survival.
A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer.
Eur J Cancer ;32A: Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: KRAS mutation is am important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res ; Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
J Clin Oncol ; Activating mutation in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
EGFR mutations in lung cancer: EGF receptor gene mutations are common in lung cancers from "never smokers" and correlate with sensitivity of tumors to gefitinib Iressa and erlotinib Tarceva. Novel DY and common secondary TM mutations in epidermal growth factor receptor- mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
- Advanced search
- The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment
- Publication - Article
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst ; Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: Differential effects of gefitinib and cetuximab on non-small-cell lung cancer bearing epidermal growth factor receptor mutations.
J Natl Cancer Inst ;97; EGFR mutations in lung adenocarcinomas: J Mol Diagn ; EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.
Am J Clin Pathol ; Correlation between morphology and EGFR mutations in lung adenocarcinomas: Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.
The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: Erlotinib in lung cancer - molecular and clinical predictors of outcome. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib 'Iressa', ZD in non-small-cell lung cancer.
Br J Cancer ; Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasia of the lung. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.